Education
About Us
Working with TipRanks
Follow Us
Roivant Sciences (ROIV)
NASDAQ:ROIV
ROIV Stock Chart & Stats
$20.27
-$0.41(-3.60%)
At close: 4:00 PM EST
$20.27
-$0.41(-3.60%)
Day’s Range― - ―
52-Week Range$8.73 - $21.35
Previous CloseN/A
Volume1.46M
Average Volume (3M)8.46M
Market Cap
$14.15B
Enterprise Value$6.46B
Total Cash (Recent Filing)$4.39B
Total Debt (Recent Filing)$98.85M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Feb 16, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding695,491,640
10 Day Avg. Volume8,769,740
30 Day Avg. Volume8,463,749
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.56
Price to Sales (P/S)251.93
P/FCF Ratio-8.67
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue317.61
Enterprise Value/Gross Profit329.42
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
$24.50Price Target Upside20.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$15.41M
Bulls Say, Bears Say
Bulls Say
Development PipelineRoivant reported positive data in DM that positions the company to have a first-in-class therapy in a disease with high unmet need and few therapeutic options.
Investment OpportunitiesRoivant will host an investor day on December 11, which is expected to provide updates on key products brepocitinib and IMVT-1402, highlighting future commercial opportunities.
Market PositionIMVT-1402 is in the lead in Graves’ disease with two ongoing registrational trials expected to readout in 2027, reinforcing its market position.
Bears Say
Data Reporting DelaysRoivant and Immunovant postponed reporting topline data from the two Phase 3 trials of batoclimab in TED for competitive reasons.
Revenue PerformanceRoivant reported total revenue of $1.6M, which is a 65% decrease year-over-year and below estimates.
Safety ConcernsRoivant expects brepo to carry class-related label safety warning.
Roivant Sciences News
ROIV FAQ
What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $8.73 and its highest was $21.35 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $14.15B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s upcoming earnings report date is Feb 16, 2026 which is in 87 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Nov 10, 2025. The company reported -$0.202 earnings per share for the quarter, beating the consensus estimate of -$0.32 by $0.118.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.31.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 695,491,640 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.202 in its last earnings report, beating expectations of -$0.32. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Roivant Sciences?
Currently, no hedge funds are holding shares in ROIV
Roivant Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (20.87% Upside)
$24.50 (20.87% Upside)
Blogger Sentiment
Bullish
ROIV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 70.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $84.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.84%
12-Months-Change
Fundamentals
Return on Equity
-14.73%
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Company Deck
ROIV Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.View all ROIV earnings summariesROIV Stock 12 Month Forecast
Average Price Target
$24.50
▲(20.87% Upside)
Technical Analysis
Ownership Overview
20.35% Insiders
13.70% Mutual Funds
31.02% Other Institutional Investors
22.30% Public Companies and
Individual Investors